Biodesix (BDSX) Set to Announce Quarterly Earnings on Friday

Biodesix (NASDAQ:BDSX) is scheduled to release its earnings data before the market opens on Friday, November 1st. Analysts expect Biodesix to post earnings of ($0.08) per share for the quarter. Biodesix has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. The business had revenue of $17.93 million during the quarter, compared to analysts’ expectations of $16.05 million. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Price Performance

Shares of NASDAQ:BDSX opened at $1.63 on Friday. The company has a 50-day simple moving average of $1.75 and a 200-day simple moving average of $1.59. Biodesix has a one year low of $1.15 and a one year high of $2.21. The company has a debt-to-equity ratio of 0.99, a quick ratio of 3.28 and a current ratio of 3.28. The stock has a market capitalization of $186.94 million, a price-to-earnings ratio of -2.96 and a beta of 1.22.

Analysts Set New Price Targets

A number of brokerages have recently commented on BDSX. Craig Hallum began coverage on shares of Biodesix in a report on Friday, July 26th. They issued a “buy” rating and a $3.00 target price for the company. Scotiabank began coverage on shares of Biodesix in a report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Biodesix has a consensus rating of “Buy” and a consensus target price of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.